Clinical Trials Logo

Clinical Trial Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)


Clinical Trial Description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03774459
Study type Interventional
Source Anavex Life Sciences Corp.
Contact
Status Completed
Phase Phase 2
Start date July 9, 2018
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Active, not recruiting NCT03608553 - A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia N/A
Recruiting NCT04148326 - A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
Recruiting NCT04389437 - OCT-Angiography and Adaptive Optics in Patients With Memory Impairment N/A
Active, not recruiting NCT02954978 - Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Phase 2
Completed NCT00988117 - The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Phase 4